Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2026
0mins
Source: Newsfilter
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.460
Low
37.00
Averages
55.86
High
68.00
Current: 54.460
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Stock Appears Undervalued
- Valuation Appeal: Bristol Myers Squibb's price-to-earnings ratio stands at approximately 16x, significantly lower than the S&P 500's 27x and the pharmaceutical industry's 24x, indicating its stock may attract value investors in the current market environment.
- Dividend Yield Advantage: The company boasts a dividend yield of 4.4%, well above the S&P 500's 1.1% and the average pharmaceutical yield of 1.7%, making it particularly appealing to income-seeking investors, despite a relatively high payout ratio of 70%.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expiration risks that could pressure its future performance, particularly with the patents for cancer drugs Revlimid and Pomalyst expiring in 2026, and cardiovascular drug Eliquis facing competition in 2028, potentially impacting revenue and profits in the near term.
- Long-Term Investment Potential: Despite short-term uncertainties, Bristol Myers Squibb's proven survival in the pharmaceutical industry and attractive valuation metrics still make it appealing for long-term investors, especially those willing to hold for decades.
See More
Arcus Biosciences Partners with Bristol Myers Squibb for Clinical Trial
- Clinical Trial Collaboration: Arcus Biosciences has entered into a clinical trial collaboration with Bristol Myers Squibb, supplying its investigational small-molecule HIF-2a inhibitor casdatifan for evaluation in the BMS-sponsored ROSETTA RCC-208 clinical trial, aimed at assessing its efficacy in advanced renal cell carcinoma.
- New Treatment Arms: The collaboration will add casdatifan combinations as two new arms of the ROSETTA RCC-208 trial, aiming to provide patients with treatment options based on HIF-2a inhibitors, thereby enhancing the effectiveness of existing therapies.
- Development Rights Retained: Under the agreement, both Arcus and Bristol Myers Squibb will retain development and commercial rights to their respective assets, ensuring independence while advancing their research agendas through this partnership.
- Strategic Development Plan: This collaboration is part of Arcus's holistic development strategy, designed to offer physicians and patients multiple treatment options, including first-line and second-line therapies, to address the treatment needs of advanced renal cell carcinoma.
See More
Dividend Outlook for Bristol Myers Squibb and Pfizer Amid Patent Challenges
- Dividend Yield Comparison: Bristol Myers Squibb boasts a forward yield of 4.4%, while Pfizer offers a higher yield of 6.6%, indicating both companies' commitment to maintaining dividends despite facing patent cliff challenges.
- Patent Risk Mitigation: Bristol Myers is set to lose exclusivity for Opdivo and Eliquis by the end of the decade, yet its new subcutaneous formulation of Opdivo is expected to attract older patients, helping to mitigate biosimilar competition pressures.
- New Drug Development Progress: Bristol Myers is developing the next-generation anticoagulant milvexian, aimed at addressing bleeding risks associated with traditional blood thinners, while its robust pipeline in oncology and immunology supports future growth prospects.
- Pfizer's Product Performance: Pfizer also faces patent expiration risks, including for its cancer drug Ibrance, but its new product Abrysvo is performing well, and the company plans to launch about 20 pivotal studies by 2025, which could drive share price recovery if successful.
See More
Dividend Outlook for Bristol Myers Squibb and Pfizer
- Dividend Yield Comparison: Bristol Myers Squibb boasts a forward yield of 4.4%, while Pfizer offers an even higher yield of 6.6%, making both companies attractive to dividend investors despite facing patent expiration challenges.
- New Drug Development: Bristol Myers is developing the next-gen anticoagulant milvexian to address bleeding risks associated with traditional blood thinners, while its new formulation of Opdivo is expected to attract older patients, mitigating biosimilar competition.
- Pfizer's Product Line: In addition to losing exclusivity for Eliquis, Pfizer will also lose patent protection for Ibrance, but its new product Abrysvo is performing well, and the company plans to launch about 20 pivotal studies in the coming years, indicating strong pipeline potential.
- Dividend Growth Trends: Bristol Myers has increased its dividend by 65.8% over the past decade, while Pfizer's dividend growth stands at 51.3%, reflecting both companies' commitment to providing stable returns to investors, with Bristol Myers slightly ahead in dividend growth rate.
See More
Citigroup Options Volume Surges Significantly
- Options Trading Volume: Citigroup (C) has seen an options trading volume of 51,324 contracts today, equating to approximately 5.1 million shares, which represents 46.2% of its average daily trading volume of 11.1 million shares over the past month, indicating a significant increase in market interest.
- High-Frequency Contracts: Among these, the $130 strike call option expiring on June 5, 2026, has been particularly active, with 10,348 contracts traded today, representing about 1.0 million underlying shares, suggesting heightened investor expectations for future price increases.
- Bristol Myers Options: Concurrently, Bristol Myers Squibb (BMY) has recorded an options trading volume of 48,911 contracts today, approximately 4.9 million shares, which is 45.1% of its average daily trading volume of 10.8 million shares over the past month, reflecting strong market activity.
- Key Contract Analysis: For BMY, the $62.50 strike call option expiring on July 17, 2026, has seen a trading volume of 32,979 contracts, equating to around 3.3 million shares, indicating a strong bullish sentiment among investors regarding this stock.
See More
Bristol Myers Squibb Stock Appears Attractive
- Valuation Appeal: Bristol Myers Squibb's price-to-earnings ratio stands at approximately 16x, significantly lower than the S&P 500's 27x and the pharmaceutical industry's 24x average, indicating potential value for investors.
- Dividend Yield Advantage: The company's dividend yield of 4.4% is notably higher than the S&P 500's 1.1% and the average drug maker's 1.7%, making it attractive for income-seeking investors.
- Patent Expiration Risks: However, Bristol Myers Squibb faces significant risks from upcoming patent expirations, particularly with key cancer drugs Revlimid and Pomalyst in 2026, and cardiovascular drug Eliquis facing competition in 2028, which could pressure future revenues.
- Long-Term Investment Commitment: Despite short-term uncertainties, Bristol Myers Squibb's proven ability to survive in the pharmaceutical industry and its long-term commitment make it appealing for investors looking to hold for decades, especially given its current valuation metrics.
See More
Bristol Myers Squibb Stock Appears Undervalued
- Valuation Appeal: Bristol Myers Squibb's price-to-earnings ratio stands at approximately 16x, significantly lower than the S&P 500's 27x and the pharmaceutical industry's 24x, indicating its stock may attract value investors in the current market environment.
- Dividend Yield Advantage: The company boasts a dividend yield of 4.4%, well above the S&P 500's 1.1% and the average pharmaceutical yield of 1.7%, making it particularly appealing to income-seeking investors, despite a relatively high payout ratio of 70%.
- Patent Expiration Risks: Bristol Myers Squibb faces patent expiration risks that could pressure its future performance, particularly with the patents for cancer drugs Revlimid and Pomalyst expiring in 2026, and cardiovascular drug Eliquis facing competition in 2028, potentially impacting revenue and profits in the near term.
- Long-Term Investment Potential: Despite short-term uncertainties, Bristol Myers Squibb's proven survival in the pharmaceutical industry and attractive valuation metrics still make it appealing for long-term investors, especially those willing to hold for decades.
See More
Arcus Biosciences Partners with Bristol Myers Squibb for Clinical Trial
- Clinical Trial Collaboration: Arcus Biosciences has entered into a clinical trial collaboration with Bristol Myers Squibb, supplying its investigational small-molecule HIF-2a inhibitor casdatifan for evaluation in the BMS-sponsored ROSETTA RCC-208 clinical trial, aimed at assessing its efficacy in advanced renal cell carcinoma.
- New Treatment Arms: The collaboration will add casdatifan combinations as two new arms of the ROSETTA RCC-208 trial, aiming to provide patients with treatment options based on HIF-2a inhibitors, thereby enhancing the effectiveness of existing therapies.
- Development Rights Retained: Under the agreement, both Arcus and Bristol Myers Squibb will retain development and commercial rights to their respective assets, ensuring independence while advancing their research agendas through this partnership.
- Strategic Development Plan: This collaboration is part of Arcus's holistic development strategy, designed to offer physicians and patients multiple treatment options, including first-line and second-line therapies, to address the treatment needs of advanced renal cell carcinoma.
See More
Dividend Outlook for Bristol Myers Squibb and Pfizer Amid Patent Challenges
- Dividend Yield Comparison: Bristol Myers Squibb boasts a forward yield of 4.4%, while Pfizer offers a higher yield of 6.6%, indicating both companies' commitment to maintaining dividends despite facing patent cliff challenges.
- Patent Risk Mitigation: Bristol Myers is set to lose exclusivity for Opdivo and Eliquis by the end of the decade, yet its new subcutaneous formulation of Opdivo is expected to attract older patients, helping to mitigate biosimilar competition pressures.
- New Drug Development Progress: Bristol Myers is developing the next-generation anticoagulant milvexian, aimed at addressing bleeding risks associated with traditional blood thinners, while its robust pipeline in oncology and immunology supports future growth prospects.
- Pfizer's Product Performance: Pfizer also faces patent expiration risks, including for its cancer drug Ibrance, but its new product Abrysvo is performing well, and the company plans to launch about 20 pivotal studies by 2025, which could drive share price recovery if successful.
See More
Dividend Outlook for Bristol Myers Squibb and Pfizer
- Dividend Yield Comparison: Bristol Myers Squibb boasts a forward yield of 4.4%, while Pfizer offers an even higher yield of 6.6%, making both companies attractive to dividend investors despite facing patent expiration challenges.
- New Drug Development: Bristol Myers is developing the next-gen anticoagulant milvexian to address bleeding risks associated with traditional blood thinners, while its new formulation of Opdivo is expected to attract older patients, mitigating biosimilar competition.
- Pfizer's Product Line: In addition to losing exclusivity for Eliquis, Pfizer will also lose patent protection for Ibrance, but its new product Abrysvo is performing well, and the company plans to launch about 20 pivotal studies in the coming years, indicating strong pipeline potential.
- Dividend Growth Trends: Bristol Myers has increased its dividend by 65.8% over the past decade, while Pfizer's dividend growth stands at 51.3%, reflecting both companies' commitment to providing stable returns to investors, with Bristol Myers slightly ahead in dividend growth rate.
See More
Citigroup Options Volume Surges Significantly
- Options Trading Volume: Citigroup (C) has seen an options trading volume of 51,324 contracts today, equating to approximately 5.1 million shares, which represents 46.2% of its average daily trading volume of 11.1 million shares over the past month, indicating a significant increase in market interest.
- High-Frequency Contracts: Among these, the $130 strike call option expiring on June 5, 2026, has been particularly active, with 10,348 contracts traded today, representing about 1.0 million underlying shares, suggesting heightened investor expectations for future price increases.
- Bristol Myers Options: Concurrently, Bristol Myers Squibb (BMY) has recorded an options trading volume of 48,911 contracts today, approximately 4.9 million shares, which is 45.1% of its average daily trading volume of 10.8 million shares over the past month, reflecting strong market activity.
- Key Contract Analysis: For BMY, the $62.50 strike call option expiring on July 17, 2026, has seen a trading volume of 32,979 contracts, equating to around 3.3 million shares, indicating a strong bullish sentiment among investors regarding this stock.
See More
Bristol Myers Squibb Stock Appears Attractive
- Valuation Appeal: Bristol Myers Squibb's price-to-earnings ratio stands at approximately 16x, significantly lower than the S&P 500's 27x and the pharmaceutical industry's 24x average, indicating potential value for investors.
- Dividend Yield Advantage: The company's dividend yield of 4.4% is notably higher than the S&P 500's 1.1% and the average drug maker's 1.7%, making it attractive for income-seeking investors.
- Patent Expiration Risks: However, Bristol Myers Squibb faces significant risks from upcoming patent expirations, particularly with key cancer drugs Revlimid and Pomalyst in 2026, and cardiovascular drug Eliquis facing competition in 2028, which could pressure future revenues.
- Long-Term Investment Commitment: Despite short-term uncertainties, Bristol Myers Squibb's proven ability to survive in the pharmaceutical industry and its long-term commitment make it appealing for investors looking to hold for decades, especially given its current valuation metrics.
See More
